ENZALUTAMIDE (XTANDI) SURVEY

The purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing castrate resistant prostate cancer (CRPC) from patients and caregivers in order to complete a patient evidence submission for a new medication for non-metastatic castration-resistant prostate cancer called Enzalutamide (Xtandi). 

We are looking for input from patients with either metastatic or non-metastatic castration-resistant prostate cancer (mCRPC) and their caregivers. The purpose of this survey is to understand the experience with Enzalutamide (Xtandi) or the need for Enzalutamide to prolong progression from non-metastatic to metastastic disease. If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.

The pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.

The survey will remain open until October 3rd, 2018.

Thank you for your participation.

Question Title

* 1. What option below best defines your current stage of prostate cancer?

Note for Caregivers:
If you are responding to this survey as a caregiver and not for a patient, please specify here and answer only the final three questions (19, 20 and 21) on the second page of this survey.

Question Title

* 2. What are the symptoms or problems you experience with prostate cancer that affect your day-to-day living and quality of life?

Question Title

* 3. Which of these symptoms are the most important to control. Please pick your top 3:

Question Title

* 4. What therapies are you using or did you use after stopping hormone therapy and/or being diagnosed as castrate-resistant (non-metastatic or metastatic)? Please check all that apply.

Question Title

* 5. How effective have the therapies listed in question 4 been at controlling symptoms and progression of prostate cancer? Please check all that apply.

  Very effective Somewhat effective Not very effective Not effective at all
Chemotherapy (e.g. docetaxel, cabazitaxel)

Second Line Hormone therapy (e.g. Enzalutamide (Xtandi), Abiraterone acetate (Zytiga))
Apalutamide (Erleada)
Clinical trial
Bone Mets / Pain Palliation

Question Title

* 6. What are adverse effects that you have experienced as a result of your treatments for metastatic prostate cancer?

Question Title

* 7. Which of these adverse effects are the most important for you to control? Please pick your top 3.

Question Title

* 8. Have you had issues accessing current therapies for metastatic prostate cancer?

Question Title

* 9. Are there any needs in your current therapy that are not yet being met?

Question Title

* 10. EXPECTATIONS OF A NEW DRUG
i.e. Have not taken Enzalutamide (Xtandi) for nmCRPC

Please complete questions 10-13 if you have not taken Enzalutamide (Xtandi) for nmCRPC. Note: Men who have non-metastatic prostate cancer can still respond as long as they haven’t taken Enzalutamide.

What would have been the impact on your quality of life if there had been a drug that could delay metastasis? You may want to consider your current needs, symptoms and side effects in your answer.

Question Title

* 11. How important do you think a drug like this is for men with prostate cancer?

T